1. Introduction {#sec0005}
===============

Despite significant progress in the advancement of medical and surgical treatment and healthcare delivery, influenza remains to be a cause of significant morbidity and mortality. According to the World Health Organization (WHO), up to 650,000 people die from influenza infection worldwide each year ([@bib0400]). Influenza also causes tremendous loss of productivity and economic burden. For example, in 2015, influenza-related direct medical costs topped \$3.2 billion while lost earnings and productivity for adults reached \$8 billion in the US ([@bib0440]).

Older adults are particularly vulnerable to influenza infection and its complications. In fact, over 90 % influenza-related mortality occur in adults aged 65 years and older ([@bib0485]; [@bib0525]). This is likely because of the multifaceted immune system remodeling during aging, leading to immune functional decline in older adults, or immunosenescence ([@bib0390]). The aging immune system also manifests a chronic low-grade inflammatory phenotype (CLIP) or inflammaging that has been implicated in the pathogenesis of almost all age-related chronic conditions including those in the cardiovascular and respiratory systems ([@bib0080]; [@bib0160]). This increased vulnerability to respiratory infections is further demonstrated by the ongoing coronavirus disease 2019 (COVID-19) pandemic as older adults suffer disproportionately high rate of severe COVID-19 disease and deaths ([@bib0460]; [@bib0620]). While the underlying mechanism for this COVID-19 susceptibility is not known at the present time, CLIP or inflammaging is hypothesized to play an important role ([@bib0025]). Older adults with chronic diseases are particularly at higher risk for influenza infection and its complications and, in turn, influenza infection may worsen their chronic conditions ([@bib0465]).

Influenza vaccination has been approved as a simple protective strategy for reducing influenza and its complications ([@bib0180]; [@bib0595]). It is considered the most effective measure for the prevention of influenza. Especially in the elderly, influenza vaccination has been shown to halve the incidence of serological and clinical influenza (in periods of antigenic drift) ([@bib0170]). Previous studies indicated that influenza vaccination is associated with a significant reduction in respiratory diseases, including influenza and secondary pneumonia ([@bib0185]; [@bib0370]; [@bib0580]), exacerbation of chronic lung disease ([@bib0375]) including chronic obstructive pulmonary disease (COPD) ([@bib0290]) and acute episodes of asthma ([@bib0555]). In recent years, growing attention has turned to cardiovascular diseases, as influenza vaccination has been linked to a significant risk reduction for cardiovascular diseases like stroke ([@bib0100]; [@bib0505]), acute coronary syndrome (ACS) ([@bib0415]; [@bib0520]), heart failure ([@bib0100]; [@bib0550]), and myocardial infarction ([@bib0100]; [@bib0365]; [@bib0505]). Influenza vaccination is also associated with a significant reduction in mortality in adults aged 65 years and older. In one study after adjusting for age, sex, and risk status, influenza vaccination was found to be associated with a 44 % reduction in all-cause mortality ([@bib0585]).

However, comprehensive analyses of the data available in the literature that are supportive of protective effects of influenza vaccination beyond influenza prevention in the general population as well as those in old age and with comorbidities are few and far between. Therefore, the objective of this study was to conduct an in-depth synthesis of the available data addressing the breadth and validity of the reported protective effects of influenza vaccination against cardiovascular and respiratory adverse outcomes and all-cause mortality in adults. To this end, we have conducted a meta-analysis of the evidence across existing studies.

2. Methods {#sec0010}
==========

2.1. Search strategy {#sec0015}
--------------------

We searched PubMed, Embase, Web of Science, and the Cochrane Library to identify all published studies comparing influenza vaccination with placebo from the database inception to November 11, 2018 and limited the search to English-language papers. The search used key terms, including influenza, influenza vaccination, cohort, case control and randomized controlled trial (RCT).

2.2. Inclusion and exclusion criteria {#sec0020}
-------------------------------------

Our study inclusion criteria were (i) reporting the association between influenza vaccination and cardiovascular diseases, respiratory diseases, and all-cause mortality risk in adults; (ii) comparing an influenza-vaccinated group with an unvaccinated control group; (iii) all RCTs, observational studies, cohort studies (including prospective, retrospective and ambispective cohort studies), and case-control studies; (ⅳ) published in English; (ⅴ) results reporting adjusted measures of association (e.g., hazard ratio, risk ratio, or odds ratio) and their 95 % confidence intervals (CIs).

We excluded studies that included children, adolescents or pregnant women; studies that measured adverse events like narcolepsy or Guillain-Barré Syndrome after taking influenza vaccination; as well as case series (including self-controlled case series), case reports, reviews, and commentaries. Additionally, studies with incomplete data or duplicate publications were excluded.

2.3. Data extraction and quality assessment {#sec0025}
-------------------------------------------

Two investigators (YYC and XXC) extracted data independently, and any disagreement was resolved by consensus or consultation with a third author (ZC). For each study, we collected the first author, journal, year of publication, study design, sample size, population demographics (including study region/country, number of males, and mean age or age range), the number of vaccinated subjects, outcomes, and fully adjusted measures of association with the corresponding 95 % CIs.

The Newcastle-Ottawa Scale (NOS) was designed for the evaluation of case-control and cohort studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). The quality of each study was graded as good, fair, or poor. To be rated as good, studies needed to meet all the criteria. A study was rated as poor when one or more domains were assessed as having a serious flaw. Studies that met some but not all of the criteria were rated as fair quality. Trail quality was determined as high quality by the Cochrane criteria if at least the first 3 criteria were accounted for, or otherwise of uncertain risk of material bias. Any disagreements or discrepancies regarding study selection, data extraction, and quality assessment were resolved by consensus. The Cochrane Collaboration was employed to evaluate the quality of each RCT ([@bib0225]).

2.4. Outcomes measures, data synthesis and analysis {#sec0030}
---------------------------------------------------

Outcomes measures for this meta-analysis included overall or composite cardiovascular outcomes and respiratory diseases as well as all-cause mortality. According to the disease outcome extracted from the original studies, the cardiovascular outcomes were further evaluated as individual conditions including stroke, myocardial infarction, ACS, heart failure, ischemic heart disease (IHD), major adverse cardiovascular events (MACEs), cardiovascular mortality, and unspecific heart disease. Similarly, respiratory outcomes were further evaluated as individual conditions, such as COPD, asthma, pneumonia, respiratory failure, respiratory infection, respiratory mortality, and unspecific respiratory disease.

We used a random-effects model to estimate the effect of the influenza vaccination. For each outcome measure of interest, we pooled the confounder-adjusted HR/OR/RR and used the Cochran's Q chi-square test and *I* ^2^ statistic to assess the heterogeneity. Subgroup analyses and sensitivity analyses were performed to assess the associations found by selected studies with risks for cardiovascular diseases, respiratory diseases, and all-cause mortality, including age, sex, seasonality, pre-exiting specific diseases (e.g., cardiovascular diseases, chronic kidney, COPD, etc.), and region/country. Finally, a funnel plot and Egger's rank were used to evaluate the publication bias. All statistical procedures used a two-sided significance level of 0.05 and were conducted by Stata v.15.0.

3. Results {#sec0035}
==========

3.1. Identification of the studies included in this meta-analysis {#sec0040}
-----------------------------------------------------------------

[Fig. 1](#fig0005){ref-type="fig"} showed a flow diagram for the identification of studies included in this meta-analysis. First, our initial search yielded a total of 53,830 articles, 33,560 articles were included after the removal of duplicates. After screening the titles and abstracts, 33,078 records were excluded because the studies did not meet the selection criteria (e.g., no related outcome \[*n* = 14,657\], influenza, not vaccination \[*n* = 11,895\], vaccination not our aim \[*n* = 4834\], comment/reply/letter \[*n* = 284\], subjects not human \[*n* = 205\], and meta-analysis \[*n* = 1203\]. Full-text articles were assessed for eligibility, 408 records were excluded because they included children or pregnant women \[*n* = 53\], did not involve influenza vaccination \[*n* = 80\], were conference abstracts \[*n* = 30\], or presented outcomes not related to our aim \[*n* = 245\]. Finally, we were left with 74 articles (including 75 studies) relevant for our meta-analysis. Among them, 47 were observational cohort studies, 22 were case--control studies, and 6 were RCTs.Fig. 1Details of study selection for meta-analysis.Fig. 1

3.2. Characteristics of included studies and quality assessment {#sec0045}
---------------------------------------------------------------

[Table 1](#tbl0005){ref-type="table"} showed the details of the included articles. These articles were published between 1999 and 2018. The sample size of the included studies ranges from 60 to 2,244,594 participants. Among the included studies, one study was performed in the Europe, two were multi-national, and others were conducted in individual countries or regions. Among the latter, eleven were in the United States, three in Argentina, two in Canada, two in France, one in Germany, three in China-Hong Kong, three in Israel, one in Italy, three in Japan, three in the Netherlands, two in Poland, one in Saudi Arabia, seven in Spain, two in Sweden, twenty in China-Taiwan, two in Thailand, one in Turkey, and five in the United Kingdom. Some of these studies \[*n* = 63\] examined mainly outcomes related to cardiovascular diseases, such as stroke, myocardial infarction, ACS, heart failure, IHD, MACEs, cardiovascular mortality, and unspecific heart disease. Others mainly examined all-cause mortality \[*n* = 43\] or respiratory diseases \[*n* = 34\] including COPD, asthma, pneumonia, respiratory failure, respiratory infection, respiratory mortality, and unspecific respiratory disease.Table 1Details of the studies included in this meta-analysis.Table 1StudyTrial designStudy area, countrySample size(total)Sample size(man)Vaccination(Yes)Age (years)Follow-up timeSpecific-diseaseOutcome measured**(**[@bib0075]**)**CohortChina-Taiwan440618352206709 yearsChronic Kidney DiseaseACS**(**[@bib0305]**)**CohortMultinational10,1086083505470---Recent ischemic stroke or TIAMACEs, Myocardial infarction, Stroke**(**[@bib0250]**)**CohortMultinational31,54618,27812,441≥556 months-5.5 yearsVascular diseaseMACEs**(**[@bib0235]**)**CohortChina-Taiwan29,17814,5816713All ages8 yearsCOPDIHD**(**[@bib0260]**)**CohortChina-Taiwan65703470254773.39 ± 9.658 yearsAtrial fibrillationStroke**(**[@bib0330]**)**CohortChina-Taiwan65703470254773.39 ± 9.658 yearsAtrial fibrillationStroke**(**[@bib0285]**)**CohortIsrael1964111501≥501−4 yearsAcute heart failureAll-cause mortality**(**[@bib0230]**)**CohortChina-Taiwan202,058101,74693,051≥651 year---Myocardial infarction**(**[@bib0245]**)**CohortChina-Hong Kong36,636---9368≥6564 weeks---Pneumonia, COPD, Asthma, Stroke, IHD, Myocardial infarction, Heart failure, All-cause mortality**(**[@bib0375]**)**CohortUS18989261366≥6511 monthsChronic lung diseaseRespiratory diseases, All-cause mortality**(**[@bib0040]**)**CohortCanada25,92210,56914,512≥651 year or until date of death---All-cause mortality**(**[@bib0405]**)**CohortSweden260,155103,62098,199≥659 month---All-cause mortality**(**[@bib0510]**)**CohortUS825145441590≥18---Community-Acquired PneumoniaAll-cause mortality**(**[@bib0565]**)**CohortNetherlands17,82271788911≥656 months---All-cause mortality, Pneumonia**(**[@bib0475]**)**CohortIsrael84,613---36,569≥654 months---All-cause mortality**(**[@bib0590]**)**CohortChina-Taiwan41781807208958.812 monthsPeritoneal dialysis patientsRespiratory failure, Stroke, Heart failure, All-cause mortality**(**[@bib0455]**)**CohortSpain265010931586≥6528 monthsDiabetesAll-cause mortality**(**[@bib0220]**)**CohortIsrael15,55679298200≥651 yearDiabetesAll-cause mortality**(**[@bib0050]**)**CohortChina-Hong Kong286107211≥6512 months---All-cause mortality, Pneumonia mortality, Cardiovascular mortality**(**[@bib0135]**)**CohortCanada704381352≥17Until death or patient dischargePneumoniaAll-cause mortality**(**[@bib0140]**)**CohortChina-Taiwan440625712254＞5512 yearsChronic Kidney DiseaseHeart failure**(**[@bib0520]**)**CohortChina-Taiwan772246313027≥5512 yearsCOPDACS**(**[@bib0380]**)**CohortUS140,05561,21877,738≥651 year---Cardiac disease, IHD, Heart failure, Stroke, All-cause mortality**(**[@bib0380]**)**CohortUS146,32865,02487,357≥651 year---IHD, Heart failure, Stroke, All-cause mortality**(**[@bib0070]**)**CohortChina-Taiwan25,60913,8603345≥558 yearsCOPDHeart failure**(**[@bib0010]**)**CohortUS491022771749≥181 yearHospitalization of influenzaAll-cause mortality**(**[@bib0265]**)**CohortTurkey65647326562 ± 1315 ± 6 monthsHeart failureHeart failure, Cardiovascular mortality**(**[@bib0020]**)**CohortSpain32291211146873.6 ± 13.24 yearsHeart failureAll-cause mortality**(**[@bib0570]**)**CohortNetherlands26,07115,1313063≥656 years---Respiratory infection, Pneumonia**(**[@bib0480]**)**CohortThailand2,244,594770,913874,22151.5 ± 18.71 year---Pneumonia**(**[@bib0060]**)**CohortChina-Taiwan16,28474508142≥7512 months---All-cause mortality, Respiratory diseases, COPD, Heart failure**(**[@bib0095]**)**CohortSweden163,391---134,045≥65------Pneumonia, Pneumonia mortality, All-cause mortality**(**[@bib0515]**)**CohortChina-Taiwan808045964434≥209 yearsChronic hepatitis B virus infectionHeart disease, Respiratory failure, All-cause mortality**(**[@bib0215]**)**CohortUS12,56658994820≥651 year---All-cause mortality**(**[@bib0295]**)**CohortItaly2082837108478.8 ± 9.512 months---All-cause mortality**(**[@bib0005]**)**CohortUK24,535------≥754 years---All-cause mortality, Cardiovascular mortality, Respiratory mortality**(**[@bib0565]**)**CohortNetherlands26,07115,13111,759≥656 years---All-cause mortality, Cardiovascular mortality, Respiratory mortality**(**[@bib0560]**)**CohortSpain129896083675.4 ± 6.940 monthsCOPDAll-cause mortality**(**[@bib0125]**)**CohortSpain134063586076.2 ± 7.13years and 3 monthsCHDAll-cause mortality**(**[@bib0330]**)**CohortChina-Taiwan504827932760Non-vaccinated:75.7 ± 7.0 Vaccinated:74.8 ± 6.34 yearsIHDAll-cause mortality, Cardiovascular diseases**(**[@bib0055]**)**CohortChina-Hong Kong18596341214Non-vaccinated:85.8 ± 7.9 Vaccinated:85.8 ± 7.51 year---All-cause mortality, Pneumonia mortality**(**[@bib0350]**)**CohortFrance43,81813,56218,671\>651 year---All-cause mortality**(**[@bib0310]**)**CohortChina-Taiwan506323703378Non-vaccinated:78.0 ± 7.6 Vaccinated:77.3 ± 7.11 year---All-cause mortality, Respiratory diseases**(**[@bib0045]**)**CohortSpain208,296---112,480≥655 months---All-cause mortality**(**[@bib0065]**)**CohortChina-Taiwan10,12511721765\>181 yearSystemic Lupus ErythematosusPneumonia, Heart disease, All-cause mortality**(**[@bib0425]**)**CohortEuropean Union3510886286684.6 ± 7.21 year---All-cause mortality**(**[@bib0335]**)**CohortChina-Taiwan33,80616,34016,903≥66---Major SurgeryPneumonia, All-cause mortality**(**[@bib0105]**)**RCTPoland65847732559.9 ± 10.3298 daysCAD/stable anginaMACEs, Cardiovascular mortality**(**[@bib0110]**)**RCTPoland65847732559.9 ± 10.3298 daysCAD/stable anginaMyocardial infarction[@bib0415]**)**RCTThailand43924922166 ± 9360 daysACSMACEs, Cardiovascular mortality, ACS, Heart failure**(**[@bib0190]**)**RCTArgentina301126151\>212 yearsACSAll-cause mortality**(**[@bib0195]**)**RCTArgentina301126151\>216 monthsMyocardial Infarction/PCIAll-cause mortality, MACEs**(**[@bib0200]**)**RCTArgentina292126151\>211 year---Cardiovascular mortality**(**[@bib0500]**)**Case-controlUS89171325525−746 years---Cardiac arrest**(**[@bib0175]**)**Case-controlGermany74051018760.6 ± 12.818 monthsIschemic or hemorrhagic stroke or TIAStroke, TIA**(**[@bib0490]**)**Case-controlUK78,70630,33915,575≥40------Myocardial infarction**(**[@bib0240]**)**Case-controlChina-Taiwan19,78811,5746226≥45≥5 years or until date of deathCOPDRespiratory failure**(**[@bib0535]**)**Case-controlChina-Taiwan172990686772.93 ± 6.121 year---Respiratory infection**(**[@bib0210]**)**Case-controlUS24858191145≥65------Myocardial infarction**(**[@bib0615]**)**Case-controlJapan15011652≥18---Idiopathic interstitial pneumoniaAll-cause mortality**(**[@bib0030]**)**Case-controlUS20,220---14,226---1 year3 End-Stage Renal DiseaseAll-cause mortality**(**[@bib0065]**)**Case-controlChina-Taiwan56,87031,67616,45170.9 ± 13.4------Atrial fibrillation**(**[@bib0085]**)**Case-controlChina-Taiwan160,72689,47462,331≥65------MACEs, Myocardial infarction, Stroke**(**[@bib0300]**)**Case-controlFrance270168149≥60------Stroke**(**[@bib0325]**)**Case-controlChina-Taiwan312016922890≥65------Stroke**(**[@bib0355]**)**Case-controlUS534279303≥49------Myocardial infarction**(**[@bib0365]**)**Case-controlUS218137123cases:62.9 ± 11.9 controls:64.6 ± 13.5---CHDMyocardial infarction**(**[@bib0420]**)**Case-controlSpain794426431cases:73.48 ± 11.45 controls:73.18 ± 10.08---Chronic Bronchitis and Acute InfectionsStroke**(**[@bib0495]**)**Case-controlUK94,02245,1687021≥18------Stroke, TIA**(**[@bib0530]**)**Case-controlUK58638029368---COPDCOPD**(**[@bib0445]**)**Case-controlSaudi Arabia51,100---17,565---------Respiratory diseases**(**[@bib0280]**)**Case-controlJapan603318≥65------Pneumonia**(**[@bib0600]**)**Case-controlJapan1609874≥65------Pneumonia**(**[@bib0255]**)**Case-controlUK796---591≥65---Acute respiratory illnessRespiratory diseases**(**[@bib0435]**)**Case-controlSpain1301---971≥65------ACS, Stroke, Pneumonia[^2][^3]

Of the 47 cohort studies, 23 were good quality, 19 were fair quality and 5 were poor quality; of the 22 case--control studies, 8 were good quality, 11 were fair quality and 3 were poor quality (details in Supplement Table A).

3.3. Cardiovascular diseases {#sec0050}
----------------------------

Influenza vaccination was associated with lower risk of adverse cardiovascular outcomes overall, with a relative risk of 0.74 (95 % CI = 0.70−0.78; [Table 2](#tbl0010){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"} ). When stratified by specific cardiovascular conditions, the results showed that influenza vaccination was associated with reduced risk of stroke (RR = 0.80, 95 % CI = 0.72−0.88), myocardial infarction (RR = 0.81, 95 % CI = 0.76−0.86), ACS (RR = 0.44, 95 % CI = 0.32−0.60), heart failure (RR = 0.60, 95 % CI = 0.44−0.83), IHD (RR = 0.83, 95 % CI = 0.77−0.90), MACEs (RR = 0.71, 95 % CI = 0.62−0.82), and cardiovascular mortality (RR = 0.78, 95 % CI = 0.65−0.94).Table 2Characteristics and main findings from the studies reporting pertinent outcomes.Table 2OutcomesNo. of studiesRelative risk\
(95 % CI)P valueI^2^ (%)Tau-squaredEgger's test**Cardiovasculardiseases630.74(0.70−0.78)0.00088.20.0250.013**Stroke150.80(0.72−0.88)0.00089.90.024Myocardial infarction100.81(0.76−0.86)0.16131.00.002Acute coronary syndrome40.44(0.32−0.60)0.00279.20.066Heart failure80.60(0.44−0.83)0.00093.50.172Ischemic heart disease40.83(0.77−0.90)0.0000.00.000MACEs90.71(0.62−0.82)0.00083.70.029Cardiovascular mortality70.78(0.65−0.94)0.12939.30.021Unspecific heart disease30.74(0.52−1.05)0.00978.70.064**Respiratory diseases340.82(0.75−0.91)0.00085.70.0520.971**COPD30.82(0.47−1.43)0.00283.60.194Pneumonia150.79(0.65−0.95)0.00086.00.078Respiratory failure30.62(0.38−1.00)0.00091.50.158Respiratory infection20.95(0.82−1.09)0.08566.30.007Respiratory mortality60.79(0.67−0.92)0.01664.30.022Unspecific respiratory diseases41.00(0.90−1.11)0.26923.60.003**All-cause mortality430.57(0.51−0.63)0.00093.60.0900.235**Fig. 2Forest plot of incident cardiovascular diseases associated with influenza vaccination.Fig. 2

In the subgroup analyses, most associations between influenza vaccination and cardiovascular risk reduction remained robust, while some were not significant. There were significant differences in the subgroup analyses according to the presence or absence of pre-existing specific diseases. Individuals with pre-existing diseases had a lower risk of 0.62 (95 % CI = 0.54−0.72), while individuals without them had a risk of 0.83 (95 % CI = 0.80−0.86; [Table 3](#tbl0015){ref-type="table"} ).Table 3Subgroup analyses of the associations between influenza vaccination and risk of cardiovascular diseases, respiratory diseases and all-cause mortality.Table 3ComponentNumber of entriesRR (95 %CI) random effects**Cardiovascular diseases**SexMen170.66 (0.58, 0.75)Women170.66 (0.59, 0.75)Age (years)\<65120.76 (0.66, 0.88)≥65320.74 (0.70, 0.79)SeasonalityInfluenza160.69 (0.63, 0.76)Non-influenza160.63 (0.54, 0.73)Pre-existing specific diseasesYes350.62 (0.54, 0.72)\
0.83 (0.80, 0.87)No280.83 (0.80, 0.87)Study designCohort300.69 (0.61, 0.79)Case-control230.82 (0.78, 0.86)RCT100.62 (0.52, 0.73)Country/RegionInternational70.77 (0.63, 0.95)Germany10.46 (0.28, 0.76)China-Taiwan190.68 (0.63, 0.74)China-Hong Kong50.87 (0.75, 1.00)United States100.81 (0.75, 0.88)France10.50 (0.26, 0.95)Spain30.25 (0.04, 1.62)United Kingdom40.86 (0.74, 1.00)Thailand40.67 (0.55, 0.81)Turkey20.51 (0.19, 1.40)Poland40.64 (0.29, 1.39)Argentina20.44 (0.28, 0.67)Netherlands10.89 (0.73, 1.08)**Respiratory diseases**SexMen or Women340.82 (0.75, 0.91)Age (years)\<6520.92 (0.70, 1.22)≥65230.86 (0.77, 0.96)Pre-existing specific diseasesYes80.69 (0.56, 0.86)No260.88 (0.80, 0.96)Study designCohort270.84 (0.75, 0.94)Case-control70.80 (0.66, 0.96)Country/RegionChina-Taiwan100.79 (0.66, 0.94)China-Hong Kong60.76 (0.67, 0.87)United States10.76 (0.53, 1.09)Spain10.31 (0.14, 0.70)United Kingdom30.84 (0.59, 1.19)Thailand41.28 (1.00, 1.65)Netherlands40.94 (0.81, 1.09)Japan20.30 (0.12, 0.76)Sweden30.91 (0.80, 1.04)**All-cause mortality**SexMen30.47 (0.32, 0.68)Women30.53 (0.32, 0.86)SeasonalityInfluenza50.56 (0.45, 0.69)Non-influenza30.79 (0.69, 0.90)Pre-existing specific diseasesYes230.50 (0.41, 0.62)No200.63 (0.56, 0.71)Study designCohort400.56 (0.50, 0.63)Case-control30.73 (0.67, 0.80)Country/RegionChina-Taiwan70.47 (0.35, 0.63)China-Hong Kong30.74 (0.62, 0.88)United States70.54 (0.45, 0.65)Israel60.49 (0.31, 0.77)Spain50.77 (0.68, 0.87)Argentina20.28 (0.10, 0.74)Netherlands20.77 (0.71, 0.83)Canada20.57 (0.45, 0.73)Sweden30.40 (0.24, 0.69)Japan20.79 (0.31, 2.03)Italy10.73 (0.56, 0.95)Europe10.80 (0.65, 0.98)United Kingdom10.89 (0.80, 0.98)France10.84 (0.76, 0.94)

3.4. Respiratory diseases {#sec0055}
-------------------------

Influenza vaccination was also associated with lower risk of adverse respiratory outcomes overall, with a relative risk of 0.82 (95 % CI = 0.75−0.91; [Table 2](#tbl0010){ref-type="table"} and [Fig. 3](#fig0015){ref-type="fig"} ). Regarding specific respiratory diseases, there were no statistically significant differences for COPD (RR = 0.82, 95 % CI = 0.47−1.43), unspecific respiratory diseases (RR = 1.00, 95 % CI = 0.90−1.11), respiratory failure (RR = 0.62, 95 % CI = 0.38−1.00), or respiratory infections (RR = 0.95, 95 % CI = 0.82−1.09). In contrast, there was a statistically significant reduction in pneumonia and respiratory mortality in those who received the influenza vaccination, with relative risks of 0.79 (95 % CI = 0.65−0.95) and 0.79 (95 % CI = 0.67−0.92), respectively ([Fig. 3](#fig0015){ref-type="fig"}).Fig. 3Forest plot of incident respiratory diseases associated with influenza vaccination.Fig. 3

In the subgroup analysis according to age, the results showed that in the group aged over 65, influenza vaccination reduced the risk of respiratory diseases (RR = 0.86, 95 % CI = 0.77−0.96), while in the group younger than 65, influenza vaccination had no significant relationship with the risk of respiratory diseases (RR = 0.92, 95 % CI = 0.70--1.22; [Table 3](#tbl0015){ref-type="table"}).

3.5. All-cause mortality {#sec0060}
------------------------

We have identified 43 studies that examined the association of influenza vaccination with all-cause mortality. The pooled estimates from these studies showed a significant risk reduction of all-cause mortality for vaccinated compared with unvaccinated individuals (RR = 0.57, 95 % CI = 0.51--0.63; [Table 3](#tbl0015){ref-type="table"} and [Fig. 4](#fig0020){ref-type="fig"} ).Fig. 4Forest plot of all-cause mortality associated with influenza vaccination.Fig. 4

In the subgroup analyses, except in Japan, the association of influenza vaccination with all-cause mortality remained statistically significant ([Table 3](#tbl0015){ref-type="table"}).

3.6. Publication bias {#sec0065}
---------------------

We conducted funnel plot analysis to check for potential publication bias, and the funnel plot was generally symmetric, indicating the absence of publication bias. This was further confirmed by a non-significant Egger's test for respiratory diseases, *P* = 0.971 and all-cause mortality, *P* = 0.235, except for that for cardiovascular outcomes, *P* = 0.013.

3.7. Sensitivity analyses {#sec0070}
-------------------------

We did sensitivity analysis excluding any trial from the pooled result. Results for the primary end point were similar when after removal of any trial from the pooled result (details in Supplement Table B).

4. Discussion {#sec0075}
=============

This meta-analysis included large cohort and case-control studies as well as RCTs evaluating potential impact of influenza vaccination on severe cardiovascular and respiratory outcomes and all-cause mortality. Our results indicated that influenza vaccination had protective effects against morbidity and mortality of cardiovascular diseases (RR = 0.74, 95 % CI = 0.70−0.78) and respiratory diseases (RR = 0.82, 95 % CI = 0.75−0.91) as well as all-cause mortality (RR = 0.57, 95 % CI = 0.51−0.63). Subgroup analyses showed that those effects of influenza vaccination were evident in the general population as well as in older adults and those with pre-existing specific diseases.

The results on composite and specific cardiovascular adverse outcomes are consistent with two meta-analyses of RCTs that demonstrate significant association between influenza vaccination and a lower risk of major adverse cardiovascular events ([@bib0115]; [@bib0545]), with a more pronounced effect in high-risk patients with recent coronary artery disease ([@bib0545]). In patients with heart failure, influenza vaccination in the previous year has been shown to reduce the risk of mortality and hospitalization ([@bib0165]; [@bib0430]; [@bib0450]). Influenza vaccination is also reported to reduce the risk of stroke ([@bib0315]; [@bib0505]; [@bib0540]).

The underlying mechanisms for the observed protective effects of influenza vaccination against cardiovascular adverse events (and all-cause mortality) are likely complex and yet to be elucidated. However, several hypotheses have been proposed. First, respiratory infections including influenza can acutely increase cardiac and pulmonary workload and burden and, thus, trigger acute cardiovascular events, particularly in individuals with existing clinical or subclinical atherosclerosis or coronary artery disease. As such, by virtue of infection prevention, influenza vaccination provides cardiovascular protection. While this is a plausible mechanism, it cannot account for the effect size of cardiovascular protective effects from influenza vaccination, particularly during mild influenza seasons. Immune modulation on chronic inflammation, i.e., aforementioned age-related CLIP or inflammaging, has also been proposed as an attractive underlying mechanism. This is because age-related CLIP or inflammaging is known to play an important role in the development of atherosclerosis, coronary artery disease, and stroke ([@bib0080]; [@bib0130]; [@bib0145]). Acutely, influenza infection can cause local and systemic inflammatory response ([@bib0345]) that can adversely impact plaque stability, leading to plaque rupture and acute cardiovascular events ([@bib0015]). Therefore, annual influenza vaccination may prevent or delay the development or progression of atherosclerosis through its immune modulation of age-related CLIP or inflammaging for the long term and prevent adverse cardiovascular events acutely through its regulation on influenza-induced inflammatory response. By extension of the latter, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes acute systemic inflammatory response or "cytokine storm" in severe COVID-19 ([@bib0360]). Whether influenza vaccination could regulate such cytokine storm and mitigate severe COVID-19 deserves further investigation. In fact, the existing Bacille Calmette-Guérin (BCG) vaccine that is not specific to SARS-CoV-2 is currently in clinical trial evaluating its potential protection against COVID-19 ([@bib0120]). Finally, regulation of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-Fn14 pathway has been proposed as a novel molecular mechanism mediating cardiovascular protective effects of influenza vaccination ([@bib0270]). TWEAK-Fn14 pathway is considered as a critical "immune switch" ([@bib0035]). Studies both in humans and in animal models suggest that activation of TWEAK-Fn14 pathway play an important role in contributing to cardiovascular diseases and their severity ([@bib0090]; [@bib0395]; [@bib0470]). Keshtkar-Jahromi and colleagues have shown that influenza vaccination significantly reduced circulating TWEAK levels in older adults, providing initial evidence supportive of this molecular mechanism that deserves further investigation ([@bib0270]).

Associations of influenza vaccination with reduced risk of overall respiratory adverse outcomes and specific respiratory conditions are not as robust or broad as those with cardiovascular outcomes and conditions. Significant protective effects of influenza vaccination against overall respiratory outcomes, pneumonia and respiratory mortality are most likely secondary to its prevention of influenza infection. These results are consistent with the data reported by Yin et al. that compared to placebo or no vaccination, dual influenza and pneumococcal vaccinations (1-odds ratio) prevents influenza by 35 % and pneumonia by 29 %; it reduces hospitalization by 18 % and respiratory mortality by 38 % ([@bib0610]). Our results indicate no significant associations of influenza vaccination with risk reduction of other respiratory infections or diseases after excluding influenza infection, nor with that of COPD and respiratory failure. Factors contributing to the development and worsening of COPD and respiratory failure are complex, and effects of influenza vaccination on these conditions require further investigation.

Data from the subgroup analyses indicate similar or slightly more robust protective effects of influenza vaccination in older adults compared to those younger than 65 years of age. This finding has significant clinical implication because of high prevalence of cardiovascular and pulmonary diseases in older adults. At the same time, this is somewhat counter intuitive, as many studies have shown reduced effectiveness of influenza vaccination in prevention of influenza infection in older adults ([@bib0185]; [@bib0205]; [@bib0385]; [@bib0575]). One likely reason is the immune modulating effects of influenza vaccination on age-related CLIP or inflammaging as described above. It may also be explained by high disease burden of cardiovascular and pulmonary conditions in older adults. Sex difference identified in this study is consistent with evidence on sex differences in immune responses to influenza vaccination reported previously ([@bib0155]; [@bib0150]; [@bib0275]) and is currently under active research of our group. Another important point about our subgroup analyses worthwhile mentioning here is that protective effects of influenza vaccination against cardiovascular and respiratory conditions as well as all-cause mortality are also evident in individuals with pre-existing diseases, emphasizing generalizability of our findings. In addition, with very few exceptions, such protective effects are present across different countries and regions.

Most previous studies have focused on one specific outcome or patient population with a specific disease. A major strength of the present study is that we used influenza vaccination as our keyword and did not limit the outcomes, enabling us to increase the chance of detecting all outcomes. Our study has several limitations. First, heterogeneity was evident within individual outcome endpoints. We only performed subgroup analyses according to age, sex, study design, study country or region, and pre-existing specific disease. Second, given the lack of more detailed study parameters such as the type or dose of influenza vaccine administered, we were unable to examine other factors that can potentially account for the observed heterogeneity. Third we extracted the adjusted estimates (OR/RR/HR), but were unable to convert them into a unified format. Finally, as the funnel plot revealed an apparent asymmetry, there are potential publication bias, language bias, and potential risk of inflated estimates by a flawed methodological design in smaller studies and/or a lack of publication of small trials with opposite results. Despite of these limitations, findings from this comprehensive and in-depth meta-analysis suggest significant protective effects of influenza vaccination against cardiovascular and respiratory adverse outcomes as well as all-cause mortality. They also provide strong evidence to support and promote influenza vaccination coverage. In the US, influenza vaccination coverage in the general adult population remains suboptimal ([@bib0340]) and the National Institute of Allergy and Infectious Disease (NIAID) of NIH has launch the universal influenza vaccine initiative ([@bib0410]). The situation in China is even more concerning as a national survey conducted from 2004 to 2014 reported vaccination coverage in China as low as 1.5 %--2% ([@bib0605]). Therefore, efforts for promoting vaccination coverage ([@bib0320]) and evidence supporting such efforts have profound public health implications, particularly in the era of the ongoing COVID-19 pandemic.

5. Conclusion {#sec0080}
=============

This meta-analysis provides comprehensive summary and synthesis of existing evidence supportive of significant associations between influenza vaccination and reduced risks for cardiovascular diseases and respiratory adverse outcomes as well as all-cause mortality. These beneficial associations are evident not only in older adults and individuals with pre-existing conditions, but also in the general adult population across different countries and regions, indicating the generalizability. The findings also point out the need for more RCTs to further evaluate and confirm the beneficial health effects of influenza vaccination on respiratory health and other important health outcomes beyond influenza prevention. They also provide supportive evidence for promoting influenza vaccination coverage with significant public health implications, particularly in the era of the ongoing COVID-19 pandemic.
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